EP0593573A1 - Pharmazeutische zubereitung die ein beta-lactam antibiotikum und clavulansäure oder ein wasserlösliches salz davon enthält - Google Patents

Pharmazeutische zubereitung die ein beta-lactam antibiotikum und clavulansäure oder ein wasserlösliches salz davon enthält

Info

Publication number
EP0593573A1
EP0593573A1 EP92914294A EP92914294A EP0593573A1 EP 0593573 A1 EP0593573 A1 EP 0593573A1 EP 92914294 A EP92914294 A EP 92914294A EP 92914294 A EP92914294 A EP 92914294A EP 0593573 A1 EP0593573 A1 EP 0593573A1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical formulation
acid
salt
formulation according
dicarboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92914294A
Other languages
English (en)
French (fr)
Inventor
David Clapham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP0593573A1 publication Critical patent/EP0593573A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP92914294A 1991-07-11 1992-07-03 Pharmazeutische zubereitung die ein beta-lactam antibiotikum und clavulansäure oder ein wasserlösliches salz davon enthält Withdrawn EP0593573A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919114950A GB9114950D0 (en) 1991-07-11 1991-07-11 Pharmaceutical formulation
GB9114950 1991-07-11
PCT/GB1992/001207 WO1993000898A1 (en) 1991-07-11 1992-07-03 Pharmaceutical formulation of a beta-lactam antibiotic and clavulanic acid or a water-soluble salt thereof

Publications (1)

Publication Number Publication Date
EP0593573A1 true EP0593573A1 (de) 1994-04-27

Family

ID=10698173

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92914294A Withdrawn EP0593573A1 (de) 1991-07-11 1992-07-03 Pharmazeutische zubereitung die ein beta-lactam antibiotikum und clavulansäure oder ein wasserlösliches salz davon enthält

Country Status (5)

Country Link
EP (1) EP0593573A1 (de)
JP (1) JPH06508844A (de)
AU (1) AU2230692A (de)
GB (1) GB9114950D0 (de)
WO (1) WO1993000898A1 (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011142730A1 (en) 2010-05-14 2011-11-17 Mahmut Bilgic Pharmaceutical composition comprising cefixime and clavulanic acid derivative compound
WO2011142731A2 (en) 2010-05-14 2011-11-17 Mahmut Bilgic Formulations comprising a third generation cephalosporin and clavulanic acid
WO2011152808A1 (en) 2010-06-03 2011-12-08 Mahmut Bilgic Formulation comprising cefpodoxime proxetil and clavulanic acid

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ318282A (en) 1995-09-07 2000-01-28 Smithkline Beecham Corp Pharmaceutical formulation containing amoxycillin and clavulanate in a weight ratio of 12:1 and 20:1
US5759579A (en) * 1996-12-05 1998-06-02 American Home Products Corporation Pharmaceutical suspension systems
DE19706978A1 (de) * 1997-02-21 1998-08-27 Ulrich Dr Posanski Kombinationspräparat für oral applizierbare Antibiotika
US20010016577A1 (en) * 1998-08-24 2001-08-23 Douglas Joseph Dobrozsi Oral mucoadhesive compositions containing gastrointestinal actives
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
EP1330236A2 (de) 2000-10-12 2003-07-30 Beecham Pharmaceuticals (Pte) Limited Amoxicillinhaltige arzneizusammensetzungen
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
CA2620675C (en) 2005-09-22 2015-04-14 Meiji Seika Kaisha, Ltd. Metallo-.beta.-lactamase inhibitors
TR201000688A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0080862B1 (de) * 1981-12-02 1985-09-25 Beecham Group Plc Pharmazeutische Zubereitung die Beta-Lactam Antibiotika enthält
GB9007945D0 (en) * 1990-04-07 1990-06-06 Beecham Group Plc Pharmaceutical formulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9300898A1 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011142730A1 (en) 2010-05-14 2011-11-17 Mahmut Bilgic Pharmaceutical composition comprising cefixime and clavulanic acid derivative compound
WO2011142731A2 (en) 2010-05-14 2011-11-17 Mahmut Bilgic Formulations comprising a third generation cephalosporin and clavulanic acid
WO2011152808A1 (en) 2010-06-03 2011-12-08 Mahmut Bilgic Formulation comprising cefpodoxime proxetil and clavulanic acid

Also Published As

Publication number Publication date
GB9114950D0 (en) 1991-08-28
JPH06508844A (ja) 1994-10-06
AU2230692A (en) 1993-02-11
WO1993000898A1 (en) 1993-01-21

Similar Documents

Publication Publication Date Title
AU722657B2 (en) Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment drug-resistant streptococcus pneumonia
US4676984A (en) Rehydratable antacid composition
EP0593573A1 (de) Pharmazeutische zubereitung die ein beta-lactam antibiotikum und clavulansäure oder ein wasserlösliches salz davon enthält
EP0862431B1 (de) Verwendung einer amoxicillin und clavulanat enthaltenden paediatrischen pharmazeutischen formulierung
EP0825860B1 (de) Verwendung einer zubereitung enthaltend amoxycillin und clavulansäure zur herstellung eines medikaments zur behandlung von bakteriellen infektionen bei pädiatrischen patienten
AU762840B2 (en) Pharmaceutical suspension formulation comprising amoxycillin, clavulanic acid and cellulose
EP1142573B1 (de) Pharmazeutische Zusammensetzungen, die Faropenem Natrium und eine Diamineacetat Verbindung zur Verbesserung der Magen-Darm Trakt Absorption enthalten
US4704278A (en) Fluidized magaldrate suspension
US6066629A (en) Storage stable amoxycillin and clavulanate suspension composition
WO1996007408A1 (en) Pharmaceutical formulations comprising clavulanic acid or derivatives and an organic acid or salt
WO2001045667A2 (en) Water-soluble powders for oral solution and use thereof
US4272542A (en) Use of di-sodium and di-potassium salts of dicarboxylic amino acids and tri- or di-sodium or potassium phosphate tartrate or citrate to improve the taste of in vivo hydrolysable esters of α-amino penicillins and cephalosporins
EP0178895B1 (de) Fluidisierte und rehydratisierbare Magaldratmischungen
US20020099044A1 (en) Composition comprising amoxycillin and clavulanic acid
EP0843552A2 (de) Pharmazeutische formulierungen
WO2000050036A1 (en) Storage stable amoxycillin and clavulanate suspension composition
EP0008178A2 (de) Pulver, Verfahren zu seiner Herstellung, es enthaltender Behälter und ein, das mit Wasser aufgearbeitete Pulver enthaltender, Sirup
EP0008179A2 (de) Pulver, Verfahren zu seiner Herstellung, es enthaltender Behälter und ein, das mit Wasser aufgearbeitete Pulver enthaltender, Sirup
AU4484199A (en) Pharmaceutical formulation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19931116

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE FR GB IT LI NL

17Q First examination report despatched

Effective date: 19980203

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980814